Here is the dividend forecast to 2029 for CSL shares

Can this blue-chip giant provide healthy dividend income?

| More on:
Man holding Australian dollar notes, symbolising dividends.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Owning CSL Ltd (ASX: CSL) shares over the past decade has been very rewarding, with good dividend growth and enormous capital growth. As shown on the chart below, the CSL share price has soared more than 200% in the past decade.

In my view, CSL may be the most impressive business on the ASX, with a market capitalisation of $100 billion. Its growth and global success are commendable.

Long-term shareholders are receiving much bigger dividends and are predicted to see even larger payments.

Let's have a look at how the CSL dividend could grow between now and the 2029 financial year.

This year, FY25

We're already close to halfway through the CSL 2025 financial year, so it won't be long before shareholders learn the FY25 interim dividend payment with the half-year result, which is expected in February 2025.

As for the annual dividend per share, UBS is currently forecasting that the CSL dividend could jump by 12% to US$2.96 per share. At the current CSL share price, that would represent a dividend yield of close to 1.7%.

UBS also considers the "possibility of a less vaccine-friendly US administration", which could impact CSL's vaccine business.

Next year, FY26

In the 2026 financial year, UBS is expecting CSL's profit to rise by more than 10%, and this can help the company's dividend rise too.

UBS is projecting that the CSL dividend could jump by another 12% to US$3.31 per share. That would represent a dividend yield of close to 1.9%. Not huge, but it's growing at a good pace.

After that, FY27

The 2027 financial year could see the business continue to grow its profit and dividend at a pleasing double-digit speed.

UBS projects that owners of CSL shares could receive an annual dividend per share of US$3.71, an increase of 12%. At the current valuation, that would represent a dividend yield of 2.1%.

Then, FY28

As an ASX healthcare share, it's quite possible that the company could deliver consistent profit growth over this period of time.

According to UBS, in the 2028 financial year, CSL could deliver a dividend increase of close to 12%, taking the annual payment to US$4.15. At the current CSL share price, that would represent a dividend yield of 2.35%.

Finally, FY29

The 2029 financial year is projected to be the best year of all – it could see yet another double-digit increase in percentage terms of both profit and dividend.

UBS forecasts that CSL's dividend could increase by another 12% in FY29 to US$4.65. At the current valuation, this payout would mean a dividend yield of 2.6%.

A 2.6% dividend yield isn't huge, but it shows how the dividend could scale upwards. Rising profit could also be exactly what investors want to see with CSL shares.

Motley Fool contributor Tristan Harrison has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended CSL. The Motley Fool Australia has recommended CSL. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

A medical researcher rests his forehead on his fist with a dejected look on his face while sitting behind a scientific microscope with another researcher's hand on his shoulder as if giving comfort.
Healthcare Shares

Mayne Pharma signals short-term pain as it resets for growth

It has been a turbulent year for Mayne Pharma after the terminated takeover bid by US company Cosette Pharmaceuticals.

Read more »

A man packs up a box of belongings at his desk as he prepares to leave the office.
Healthcare Shares

Regis Healthcare shares down 2% as CEO resigns

Dr Mellors will step down as CEO after more than six years in the role.

Read more »

Beautiful young woman drinking fresh orange juice in kitchen.
Healthcare Shares

Telix shares storm higher on big US and China news

Let's see why this biotech is getting attention on Monday.

Read more »

A Sonic Healthcare medical researcher wearing a white coat sits at her desk in a laboratory conducting a COVID-19 test
Healthcare Shares

Clinical trial of potential diabetes and arthritis treatment delivers positive results

This drug developer has reported positive results from a phase one trial.

Read more »

Doctor sees virtual images of the patient's x-rays on a blue background.
Blue Chip Shares

Is now the time to buy Pro Medicus shares?

After a 13% pullback, Pro Medicus shares are back in focus. Is this weakness an opportunity?

Read more »

Business people discussing project on digital tablet.
Healthcare Shares

Where will CSL shares be in 5 years?

Would it be a good time to buy and hold this fallen giant? Let's find out.

Read more »

Six smiling health workers pose for a selfie.
Healthcare Shares

Up 657% in a year, 4DMedcial shares rocketing another 20% today on big US news

ASX investors can’t get enough of 4DMedical shares today. Let’s see why.

Read more »

Health professional working on his laptop.
Healthcare Shares

NIB shares edge higher on profit update

Let's see why this private health insurer is in the news today.

Read more »